Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...
A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results